(Q35779318)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15155147%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

title

Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15155147%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15155147%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Jason E Stout

series ordinal

1

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15155147%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Safety

28 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15155147%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15155147%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15155147%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

187-198

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15155147%20AND%20SRC:MED&resulttype=core&format=json

The growing burden of tuberculosis: global trends and interactions with the HIV epidemic

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Evidence of a "Silent" Bacillemia in Primary Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Isoniazid induction of antinuclear antibodies. A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Adverse cutaneous reactions to antituberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Drug treatment for tuberculosis during pregnancy: safety considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Potentially Serious Side Effects of High-dose Twice-weekly Rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Glycoprotein Ib/IX complex is the target in rifampicin-induced immune thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

The role of pyrazinamide in tuberculosis chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American He

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County, Florida

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Twice weekly tuberculosis preventive therapy in HIV infection in Zambia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Prevalence of human immunodeficiency virus, hepatitis B, and hepatitis C among homeless persons with co-occurring severe mental illness and substance use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Adherence to isoniazid prophylaxis in the homeless: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

A tuberculin screening and isoniazid preventive therapy program in an inner-city population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Outbreak of Tuberculosis Among Homeless Persons Coinfected with Human Immunodeficiency Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.187

21 January 2018

Identifiers

DOI

10.1517/14740338.3.3.187

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15155147%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference